Flexion Therapeutics — Q2 2021 Earnings Presentation
5 slides from Flexion Therapeutics's earnings presentation, Aug 4, 2021
Slide 1: Q2 2021 Commercial Metrics Overview
Q2 2021 Commercial Metrics Overview August 4, 2021 Exhibit 99.2
Slide 2: Commercial Overview: Q2 Performance Metrics
ZILRETTA® net sales of $28.2 million in Q2 2021 In Q2 2,105 accounts purchased ZILRETTA Of the 2,105 accounts that purchased in Q2, 90% had purchased in a prior quarter Commercial Overview: Q2 Performance Metrics Flexion primarily sells ZILRETTA to specialty distributors; Flexion recognizes ZILRETTA
Slide 3: ZILRETTA Net Sales by Quarter
ZILRETTA Net Sales by Quarter Flexion recognizes ZILRETTA sales upon receipt of product by specialty distributors.
Slide 4: ZILRETTA Demand by Quarter
ZILRETTA Demand by Quarter Flexion primarily sells ZILRETTA to specialty distributors; Flexion recognizes ZILRETTA sales upon receipt of product by distributors; demand refers to end-user account purchases (physicians, clinics, and certain medical centers or hospitals) who purchase from these specia
Slide 5: In Q2, ~42% of Demand Came from Accounts Purchasing More than 100 Units
In Q2, ~42% of Demand Came from Accounts Purchasing More than 100 Units Flexion primarily sells ZILRETTA to specialty distributors; Flexion recognizes ZILRETTA sales upon receipt of product by distributors; demand refers to end-user account purchases (physicians, clinics, and certain medical centers